摘要
AD的鉴别诊断任因与其它痴呆的重叠特征而存在困难。用于AD鉴别诊断的生物标记物可以提高该病的诊断价值并确保恰当治疗。该研究目的在于评价两个作为AD鉴别诊断血清生物标记物的新抗原表位Tau片断的潜力。 新抗原表位Tau片断在一群代表性的患有AD,MCI,其它痴呆或非痴呆向关的记忆力减退的受试者中进行评价。两种新抗原表位Tau片断是ADAM10产生的片断(Tau-A)和半胱天冬酶3产生的片断(Tau-C)。该研究已分别用两种竞争性ELISA检测Tau-A和Tau-C测量这些片断的血清水平。 Tau-A和Tau-C能将患有AD和MCI的受试者与其它痴呆患者区分(p < 0.0042 和p < 0.05),且Tau-A能将AD和MCI患者与非痴呆相关的记忆力减退受试者区分(p <0.05)。Tau-A与CSF生物标记物t-Tau和p-Tau相比,显示了明显更高的对AD和MCI受试者与其它痴呆患者的区分。Tau-A 区分AD和MCI受试者与其它痴呆患者的能力被与CSF Aβ1-42, t-Tau/Aβ1-42 和 p-Tau/Aβ1-42比较。当CSF生物标记物与年龄和BMI与Tau-A联合使用时(AUC = 0.87,95% CI: 0.75-0.94)(p < 0.0001),诊断组间的区分度显著提高。结论是,该研究表明血清中检测出的新抗原表位Tau片断能为AD鉴别诊断提供指导。
关键词: 老年痴呆,鉴别诊断,血清生物标记物,Tau片断。
Current Alzheimer Research
Title:Serum Fragments of Tau for the Differential Diagnosis of Alzheimer's Disease
Volume: 12 Issue: 9
Author(s): D. Inekci, K. Henriksen, T. Linemann, M.A. Karsdal, A. Habib, C. Bisgaard, F.B. Eriksen and O.J. Vilholm
Affiliation:
关键词: 老年痴呆,鉴别诊断,血清生物标记物,Tau片断。
摘要: Differential diagnosis of AD is still a challenge due to overlapping features with other types of dementia. Biomarkers for the differential diagnosis of AD can improve the diagnostic value of the disease and ensure an appropriate treatment of patients. The aim of this study was to evaluate the potential of two neo-epitope fragments of Tau as serum biomarkers for differential diagnosis of AD.
The neo-epitope fragments of Tau were assessed in a cross-sectional cohort of subjects with AD, MCI, other dementias or subjects with non-dementia related memory complaints. The two Tau neo-epitope fragments were an ADAM10-generated fragment (Tau-A) and a caspase-3-generated fragment (Tau-C). The serum levels of the fragments were measured by two competitive ELISAs detecting Tau-A and Tau-C, respectively.
Tau-A and Tau-C were able to separate subjects with AD and MCI from those with other dementias (p < 0.0042 and p < 0.05), and Tau-A could also discriminate between AD and MCI patients and subjects with non-dementia related memory complaints (p < 0.05). Tau-A showed a significantly greater discrimination between AD and MCI subjects and patients with other dementias when compared to CSF biomarkers t-Tau and p-Tau. The ability of Tau-A to differentiate between AD and MCI from other dementias was comparable with CSF Aβ1-42, t-Tau/Aβ1-42 and p-Tau/Aβ1-42. The separation between the diagnostic groups was significantly improved when the CSF biomarkers as well as age and BMI were used in combination with Tau-A (AUC = 0.87, 95% CI: 0.75-0.94) (p < 0.0001). In conclusion, this study shows that a neoepitope fragment of Tau detected in serum can provide guidance on the differential diagnosis of AD.
Export Options
About this article
Cite this article as:
D. Inekci, K. Henriksen, T. Linemann, M.A. Karsdal, A. Habib, C. Bisgaard, F.B. Eriksen and O.J. Vilholm , Serum Fragments of Tau for the Differential Diagnosis of Alzheimer's Disease, Current Alzheimer Research 2015; 12 (9) . https://dx.doi.org/10.2174/1567205012666150710111211
DOI https://dx.doi.org/10.2174/1567205012666150710111211 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Is Nitric Oxide Assuming a Janus-Face in The Central Nervous System?
Current Medicinal Chemistry Progranulin Mutations in Ubiquitin-Positive Frontotemporal Dementia Linked to Chromosome 17q21
Current Alzheimer Research Antiplatelets in Stroke Prevention
Current Vascular Pharmacology Low-Cost Anti-HIV Compounds: Potential Application for AIDS Therapy in Developing Countries
Current Pharmaceutical Design Prematurely Aged Children: Molecular Alterations Leading to Hutchinson-Gilford Progeria and Werner Syndromes
Current Aging Science Persons with Co-Existing Neurological Disorders: Risk Analysis, Considerations and Management in COVID-19 Pandemic
CNS & Neurological Disorders - Drug Targets Proinflammatory Cytokines and Chemokines in Neonatal Brain Damage
Current Pediatric Reviews Genetic Predisposition to Parkinson’s Disease and Cancer
Current Cancer Drug Targets Moving to the Rhythm with Clock (Circadian) Genes, Autophagy, mTOR, and SIRT1 in Degenerative Disease and Cancer
Current Neurovascular Research <i>In Vivo</i> Longitudinal Monitoring of Changes in the Corpus Callosum Integrity During Disease Progression in a Mouse Model of Alzheimer’s Disease
Current Alzheimer Research Cannabinoids and Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Effects of Exercise and Ferulic Acid on Alpha Synuclein and Neuroprotective Heat Shock Protein 70 in An Experimental Model of Parkinsonism Disease
CNS & Neurological Disorders - Drug Targets Estrogen Receptors as Targets for Drug Development for Breast Cancer, Osteoporosis and Cardiovascular Diseases
Current Cancer Drug Targets Pharmacotherapy of Sickle Cell Disease in Children
Current Pharmaceutical Design Beneficial Effects of Bioactive Phospholipids: Genomic Bases
Current Nutrition & Food Science Calcineurin Inhibition and Protein Kinase A Activation Limits Cognitive Dysfunction and Histopathological Damage in a Model of Dementia of the Alzheimer’s Type
Current Neurovascular Research Dementia and the Default Mode
Current Alzheimer Research Music Therapy for Individuals with Dementia: Areas of Interventions and Research Perspectives
Current Alzheimer Research A Comprehensive Study of Pharmacological Behaviors, Nano-Formulations, and Applications of Rosemary
The Natural Products Journal Phyto-derived Products as Matrix Metalloproteinases Inhibitors in Cardiovascular Diseases
Current Hypertension Reviews